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Abstract
In the recent years, sequence-specific nucleases such as ZFNs, TALENs, and CRISPR/Cas9 have revolutionzed the fields of
animal genome editing and transgenesis. However, these new techniques require microinjection to deliver nucleic acids
into embryos to generate gene-modified animals. Microinjection is a delicate procedure that requires sophisticated
equipment and highly trained and experienced technicians. Though over a dozen alternate approaches for
nucleic acid delivery into embryos were attempted during the pre-CRISPR era, none of them became routinely
used as microinjection. The addition of CRISPR/Cas9 to the genome editing toolbox has propelled the search for
novel delivery approaches that can obviate the need for microinjection. Indeed, some groups have recently developed
electroporation-based methods that have the potential to radically change animal transgenesis. This review provides
an overview of the old and new delivery methods, and discusses various strategies that were attempted during the last
three decades. In addition, several of the methods are re-evaluated with respect to their suitability to deliver genome
editing components, particularly CRISPR/Cas9, to embryos.
Reviewers: Drs. Eugene Koonin and Haruhiko Siomi.
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Background
Targeted gene inactivation via homologous recombin-
ation (HR) using embryonic stem (ES) cells has been a
powerful tool to evaluate the function of a gene of inter-
est (GOI) in vivo [1]. However, the use of this technique
has been hampered by several factors, including: the low
efficiency of targeting in ES cells; the need for time-
consuming and labor-intensive screening of ES clones;
the maintenance of clones under undifferentiated states;
chimeric mouse production; and breeding chimeras to
obtain germ-line transmission of the mutation.
Recently, genome editing using sequence-specific nucle-
ases has emerged as a new tool for achieving targeted mu-
tations in GOI in a wide variety of cell types and organisms
[2–4]. To date, three different systems—zinc-finger
nuclease (ZFN), transcription activator-like effector nucle-
ase (TALEN), and clustered regulatory-interspaced short
palindromic repeats (CRISPR/Cas: CRISPR-associated 9
and CRISPR/Cas9—use sequence-specific nucleases for ef-
ficient and precise genetic modifications. They induce tar-
geted double-strand breaks (DSBs), which stimulate cellular
DNA repair mechanisms such as non-homologous end
joining (NHEJ) and homology-directed repair (HDR) [5, 6].
Owing to the ease of its design and flexibility, the CRISPR/
Cas9 system is now widely used for producing genetically
modified animals, including the mouse [7].
Animal genome engineering labs have readily adapted
these newer technologies. Nevertheless, the delivery of
these nucleic-acid tools to embryos still relies on the
three-decades-old transgenic procedures of embryo iso-
lation, micro-injection, and transfer of embryos to recip-
ients. These traditional transgenic techniques require
expensive micromanipulator systems and highly skilled
technical personnel to perform the procedure. Develop-
ing newer methods can obviate the need for expensive
equipment and highly skilled personnel.
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Over the past three decades, several methods have been
described for delivering transgenic DNA through various
modes, such as pre-implantation embryos/fetuses, ovarian
cells (including oocytes), and testicular cells (including
sperm), to achieve a desired genetic change in the off-
spring. While such methods have been partially successful
in reaching the embryos in situ, additional strategies are
necessary to efficiently deliver genome editing compo-
nents. The latest additions to these approaches include
electroporation-based methods that bypass microinjec-
tion. One of the most recent methods developed by us
also bypasses the isolation and transfer of embryos into
recipient animals.
Here, we review over a dozen different gene delivery
approaches that were tried but did not become commonly
used approaches. In light of recent advances in CRISPR/
Cas9 technology, which requires the development of
simpler and better electroporation-based approaches, the
large array of gene delivery methods that had been previ-
ously tried could be re-visited and fine-tuned to establish
their suitability for use with CRISPR gene editing tools.
These delivery approaches are discussed below (sections Ex
vivo delivery to pre-implantation embryos and to sperm, In
vivo delivery to pre-implantation embryos, fetuses, and ovar-
ian tissues & In vivo delivery to male gonadal tissues) under
three broad sections: Ex vivo delivery to pre-implantation
embryos and sperm; In vivo delivery to pre-implantation
embryos, fetuses and ovarian tissues; and In vivo delivery to
male gonadal tissues. Various nucleic acids delivery methods
discussed in this review are listed in Table 1.
Ex vivo delivery to pre-implantation embryos and
to sperm
Pronuclear injection (PI)
Microinjection of purified DNA, commonly known as
pronuclear injenction (PI), into the pronuclei of zygotes
to produce Tg mice was first demonstrated by Gordon
et al., 1980 [8] (schematically shown in Fig. 1a). Since
then, the PI method has been perfected and used in
many labs; they are primarily used to introduce a trans-
gene harboring the GOI into the genome to generate Tg
animals. PI technique involves the micro-injection of
purified nucleic-acids into fertilized eggs (or pronuclei),
and until recently, the PI approach was thought to be
impossible for generating knock-out (KO) and knock-in
(KI) animals. It was demonstrated for the first time that
Table 1 Nucleic acids delivery methods in animal transgenesis and genome editing
Category Method Remarks Germ line transmission potential
Ex vivo approaches Pronuclear injection The most commonly used method followed
by thousands of labs for over 3 decades
High
Viral Vectors A few labs used. Limited success. High when lentiviral vectrs are used
Receptor-mediated uptake Only one report [28]. Not proven
In vitro electroporation Novel approach: also proven using CRISPR system. High
Liposomal transfection Very few labs used. Limited success. Not proven
Blastocyst microinjection Only one report [32]: may be suitable for








Very few labs have attempted. Limited success. Low
In vivo delivery to
pre-implantation embryos,
fetuses and ovarian tissues
GONAD Only one report [50]. This method completely
eliminates the need for isolation, microinjection
and transfer of embryos to recipient mice. Only
one recent so far, yet to be tested in other labs.
Not proven yet, but highly likely
Trans-placental gene delivery
to fetuses
Very few labs have attempted. Limited success. Very low
Delivery to fetal tissues in utero Very few labs have attempted. Limited success. Very low
In vivo delivery to ovarian tissues Very few labs have attempted. Limited success. Low




Several labs have attempted. Limited success. Possible, may need to screen many
offspring from the treated males
Seminiferous tubule-mediated
gene delivery
A few labs have attempted. Limited success.
Gene delivery via vas deferens Very few labs have attempted. Limited success.
Nucleic acids delivery to the
cauda epididymis
Very few labs have attempted. Limited success.
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KO models could be generated by direct PI approach by
injecting ZFNs; these were first introduced in 2009 for
genome editing [9]. Other, newer techniques such as
PITT (Pronuclear Injection-based Trageted Transgen-
esis) [10], TALENs, and CRISPR/Cas9 systems have
employed PI to generate KO/KI animals. Though PI is
a fairly simple and rapid method for the creation of
KO animals compared to traditional, targeted gene
modification systems using ES cells, PI requires the
use of expensive micromanipulation equipment and
skilled peronnel to operate the equipment.
Delivery through retrovirus, lentivirus, and adenovirus
infections
Although less common, viral delivery systems are used
as delivery agents for Tg DNA by infecting pre-
implantation embryos with viral vectors, such as a retro-
virus [11–13], lentivirus [14] or adenovirus [15, 16]. A
seminal experiment of viral vector delivery was reported
by Tsukui et al., 1996, who used a replication-defective
adenovirus vector carrying lacZ to zona pellucida (ZP)-
free mouse zygotes [16] (schematic shown in Fig. 1b).
The authors also demonstrated the presence of trans-
genes in the genomes of the live offspring. Many
subsequent attempts using retroviral and lentiviral vec-
tors (not cited here) suggest that transgenesis via the
viral infection of early embryos is effective approach to
create Tg animals.
The two major advantages of an adenoviral system
that are particularly suited for delivery of CRISPR tools
are that i) adenoviruses, unlike retro-/lenti-viruses, do
not need to be integrated into the genome [17]; and ii)
adenoviruses generally have higher infection efficiency
than retro-/lenti-viruses. Adenoviral systems have been
reported to be superior to lentiviral systems for accurate
genome editing with engineered nucleases in human
cells [18]. Adeno-associated virus (AAV) is an alternative
choice for delivery of CRISPR/Cas9 components. AAV is
a versatile and safe vector system and is used in thera-
peutic applications but one of the limitation of AAV is
its small cargo size that it can accommodate (around
4.5 kb in length). While wildtype Cas9 is not suitable for
packaging into AAV, a recently identified Cas9 from
Staphylococcus aureus (saCas9) could be packaged into
AAV because of its shorter size [19]. A major, inconveni-
ent step required for using viral vectors is the preparation
and concentration of viral particles prior to infection, both
time-consuming and labor-intensive.































Fig. 1 Schematic showing various Knoc-kout/Knock-In (KO/KI) and Transgenic (TG) mice generation approaches reviewed in the article. Only the
methods that have potential for generating germ-line transmitted offspring are shown (see text for additional methods that may not have germ-
line transmission potential). (A) The classical methods that require microinjection are shown in inner circle, [*; the CRISPR system can generate KO/KI
models directly through PI and therefore can by-pass the use of ES cells]. (B) The approaches that do not require microinjection are listed in the middle
circle (those in the dark gray shaded area do not require ex vivo handling of embryos). (C) The GONAD method that does not require both microinjec-
tion- and ex vivo handling- of embryos, is listed in the outer circle
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In vitro electroporation
Grabarek et al., 2002 demonstrated for the first time that
nucleic acids can be efficiently delivered to isolated oo-
cytes and zygotes by electroporation [20]. One disadvan-
tage of this method, however, is that the ZP must be
removed, and this often hampers the effective uptake of
DNA. Also, ZP-free embryos cannot survive in vivo,
since they tend to be trapped by the inner surface of the
oviductal wall due to their adhesiveness, leading to re-
duced pregnancy rates among the embryo-recipient ani-
mals [21, 22]. To overcome this issue, in vitro cultivation
of treated zygotes was considered to develop further into
blastocysts and for subsequent transfer to recipient fe-
males. Grabarek et al., 2002 tried an alternative strategy to
weaken the ZP by a brief treatment with acidic Tyrode’s
solution, which then allowed the enhanced uptake of ex-
ogenous DNA and protected the embryos from electro-
poration damage [20]. Many groups subsequently tried
the zona weakening strategy and succeeded in
electroporation-mediated delivery of nucleic acids to early
embryos [23, 24].
The first successful genome editing in isolated rat zy-
gotes through electroporation was reported in 2014 by
Kaneko et al., [25], who used in vitro electroporation-
mediated gene delivery (shown in Fig. 1c), and reported
up to 73 % efficiency with this approach in genome edit-
ing by delivering TALENs or CRISPR/Cas9. A new elec-
troporation apparatus, called NEPA 21 (NEPA GENE),
was used in this report: the apparatus generates a set of
electric pulses that are mainly comprised of poring
pulses and transfer pulses. The poring pulse creates a
transient poration of the cell membrane, and the tranfer
pulse elicits the transfer of exogenous DNA into the cell
or embryo via the pores (http://www.nepagene.jp/
index2.html). According to the authors, electroporation
with the defined set of pulses resulted in efficient nucleic
acid-delivery, and resulted in increased embryo viability.
Using this method, a large number of embryos (~100)
can be handled at once, as opposed to micro-injection
performed on one embryo at a time, and this method
does not require ZP weakening. The success of the
Kaneko's group may be attributed to the capabilities of
NEPA 21 itself, which permits the rapid transfer of ex-
ogenous DNA inside the cells and embryos, while redu-
cing cellular damages caused by electrical heating. Soon
after this report, two other groups used in vitro electro-
poration for successful genome editing in pre-
implantation embryos [26, 27], although they employed
electroporators that were different from NEPA 21. Even
though “in vitro electroporation in isolated embryos”
made a significant advance in delivering nucleic acids to
embryos, this method still requires that embryos be iso-
lated, handled outside the animal, and transferred back
to a different set of females.
Nucleic acid delivery via receptor-mediated uptake
This method relies on the uptake of exogenous DNA
via receptors expressed on the surface of cells and em-
bryos. The “receptor-mediated gene transfer” was first
demonstrated by Ivanova et al., 1999 [28]. Mouse and
rabbit pre-implantation embryos were incubated with
intact ZPs for 3 h with plasmid DNA- containing insu-
lin as an internalizable ligand, and it was observed that
the constructs penetrated the ZP and accumulated in
the peri-nuclear space of the blastomere. The exogen-
ous DNA was also confirmed as integrated into the
genome of fetuses and newborns that were derived
from the treated embryos. According to the authors,
the construct containing DNA and insulin does not bind
to the ZP, but penetrates inside to accumulate in the peri-
nuclear space of the embryos at various stages, from zyg-
ote to morula. Although this approach has not become
popular, it suggests that delivery via receptor-mediated
uptake can be used for the creation of genome-edited ani-
mals without resorting to PI- or electroporation-based
approaches.
Liposomal transfection
The ZP-denuded preimplantation embryos were suc-
cessfully transfected with plasmid DNAs, similar to
liposome-mediated transfection in cultured cells [29, 30]
(shown in Fig. 1d). However, the transfection efficiency
was relatively low, attributed to ZP acting as a barrier and
preventing transfection. Furthermore, Tg founders were
obtained by transferring the liposomally transfected em-
bryos to the reproductive tract of recipients, although its
overall efficiency was only 1.27 % [30]. Although these
methods did not result in germ line transmission of
transgenes, there are some advantages of liposome deliv-
ery: i) it does not require sophisticated equipment (such
as micromanipulator or electroporator); ii) it is less toxic
than electroporation; and iii) a large number of embryos
(~100) can be processed simultaneously. On the other
hand, this method suffers similar shortcomings as others,
as shown for in vitro electroporation, because it requires
ZP-denuded (not ZP-intact) embryos, the use of which
leads to reduced pregnancy rates in recipient animals.
Notably, Joo et al., 2014, recently developed a hydrophilic
and Cy5.5-labeled organic compound called VisuFect,
and it was demonstrated that VisuFect that had been
conjugated with poly(A) oligo (referred to as ‘VFA’)
successfully penetrated through the ZP of the fertilized
eggs of various species, including those of pigs, zebra-
fish, fruit flies, and mice [31]. This suggests that Visu-
Fect could be used to deliver genome-editing nucleic
acids to ZP-intact embryos to generate genetically
modified animals without affecting pregnancy rates in
the recipient animals.
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Blastocyst microinjection
This method is intended to deliver nucleic acids directly
to cells in the inner cell mass (ICM), a precursor of the
fetus, in a blastocyst. This approach was first demon-
strated by Jaenisch and Minz, 1974, who microinjected
simian virus 40 (SV40) viral DNA into the cavity (called
the ‘blastocoel’) of the blastocyst [32] (shown in Fig. 1e);
this resulted in successful infection of a portion of cells
in both the trophectodermal layer and the inner cell
mass (ICM). After surgical transfer to recipient females,
approximately 40 % of the founders born possessed the
exogenous DNA in the genomes of some organs; how-
ever, the germ line transmission of the genetic mutation
was not demonstrated in this report. This method is not
followed routinely for the obvious reason that not all
cells will take the foreign nucleic acids, and leads to a
high degree of mosaicim and the need to extensively
screen several independent offspring, even if germ line
transmission occurs. This method requires a microma-
nipulator system for micro-injection, and also requires
the transfer of treated blastocysts into the uteri of recipi-
ent females.
Sperm-mediated gene transfer (SMGT)
Lavitrano et al., 1989 [33] demonstrated for the first time
that brief incubation of spermatozoa, isolated from cauda
epididymides and with circular plasmids, resulted in the
adhering of spermatozoa to DNA (shown in Fig. 1f).
When these DNA-bound spermatozoa were used in in
vitro fertilization (IVF) with oocytes, the resulting zygotes
harbored the exogenous DNA in their genome. This
method was called “sperm-mediated gene transfer”
(SMGT). Because of its simplicity and it did not require
expensive micromanipulator systems, this technology was
regarded as a more convenient tool for the production of
Tg animals than the PI-based transgenesis. This technique
was later tried in many laboratories, but results have been
mixed [34, 35]; so far, only a limited number of laborator-
ies have reported successful data using SMGT [36–39]. If
the delivery of CRISPR/Cas9 genome-editing components
is attempted through SMGT, sperm might need to be in-
cubated in a medium containing the plasmid DNA that
encodes Cas9 and single-guide (sg)RNA or mRNA for
Cas9 and sgRNA. As mentioned above, SMGT is a very
simple method: if successful genome editing using this
system is successfully developed, it can be used routinely.
Intracytoplasmic sperm injection-mediated gene transfer
(ICSI-MGT)
It is possible to generate live offspring by microinjecting
inactive or dead spermatozoa into the cytoplasm of a
normal oocyte. This was first demonstrated by Lin, 1969
[40], and is now called intracytoplasmic sperm injection
(ICSI). Perry et al., 1999 [41], demonstrated that Tg mice
can be produced when dead spermatozoa incubated with
exogenous DNA are microinjected into normal eggs
(shown in Fig. 1g). Since this first demonstation, this
transgenesis technology has been tried by others and
called by different names such as ICSI-MGT or TransICSI
[38, 42, 43]. This technology is particularly useful for the
introduction of larger transgenes derived from bacterial
artificial chromosomes (BAC) into the animal genome
[44, 45].
In vivo delivery to pre-implantation embryos,
fetuses, and ovarian tissues
The approaches mentioned in Section "Ex vivo delivery
to pre-implantation embryos and to sperm" involve the
isolation of zygotes, oocytes, sperm, and embryos, their
ex vivo treatment to deliver nucleic acids, and subse-
quent transfer to recipient females for further develop-
ment. In this section, we summarize the methods that
do not need isolation and ex vivo handling steps, but
that can deliver the nucleic acid directly in situ.
GONAD
Delivery of liposomally encapsulated DNA directly into
the oviductal lumen was first reported by Esponda’s
group [46, 47] (shown in Fig. 2h). In 2005, we attempted
to deliver plasmid DNA to oviductal epithelium by in
vivo instillation into oviductal lumen (ampulla) at Day
0.4 of pregnancy (corresponding to the zygote stage),
and by subsequent in vivo electroporation towards the
entire ovuduct using tweezer-type electrodes [48]. The
plasmid DNA was delivered in up to 43 % of the ovi-
ductal epithelium; we named the method gene transfer
to oviductal epithelium (GTOVE). This approach was
initially meant to deliver DNA to the zygotes residing at
the ampulla, but we failed to accomplish this goal. In all
Fig. 2 Ex vivo delivery methods to pre-implantation embryos and sperm
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likelihood, the presence of cumulus cells surrounding
the oocytes might have acted as a barrier hindering
DNA uptake by the zygotes. We then tried the tech-
nique at day 1.6 (~14:00 h on the day of procedure) of
pregnancy, believing that the cumulus cells might be
detached from the embryos at this stage, and that gene
delivery to the embryos might therefore occur. This, in-
deed, turned out to be the case: we observed that fluor-
escent 4–8 cell embryos that had been isolated from
the oviducts dissected 1 day after GTOVE using EGFP
plasmid [49]. Unfortunately, chromosomal integration
of the exogenous DNA was not achieved in offspring
analyzed at the mid-gestational stage. The transient na-
ture of this transgene expression then prompted us to
test the CRISPR/Cas9 system, which causes indel muta-
tions at the target locus in 2-cell embryos through a
hit-and-run mechanism, with the CRISPR components
only having to cleave the genomic DNA without need-
ing to integrate into the genome. Further, we recently
demonstrated that the instillation of Cas9 mRNA and
sgRNA into the oviductal lumen at day 1.6 of gestation
and subsequent in vivo electroporation using a T820
electroporator (BTX, San Diego, CA, USA) resulted in
the generation of embryos and fetuses with mutations
at the target locus [50]. The efficiency of mutations
among the fetuses isolated was relatively low: of the 25
fetuses obtained, only 7 of them (28 %) had mutations
[50]. Nevertheless, these data clearly indicate that in
vivo genome editing by direct delivery of genome edit-
ing components to preimplantation embryos is possible.
Accordingly, we re-named this technology as Genome-
editing via Oviductal Nucleic Acids Delivery (GONAD)
[50].
GONAD technology is the simplest and most conveni-
ent method among all the existing gene delivery systems
targeted to pre-implantation embryos. It does not re-
quire many complex steps for animal transgenesis, such
as: (i) isolation of embryos; (ii) ex vivo handling and cul-
turing of embryos; (iii) manipulation of embryos such as
microinjection; or (iv) microsurgery to transfer embryos
to recipient females. GONAD can be used for genome
editing in other species where ex vivo handling of iso-
lated zygotes is considered difficult (for example, pigs
and calves). The original GONAD was performed at the
2-cell stage, where it often caused mosaic patterns of
gene expression [50]. One of the obvious reasons for
such mosaicism could be that the components intro-
duced by GONAD (such as EGFP or Cas9 mRNA and
sgRNA) might have differed between the two blasto-
meres at the 2-cell embryo stage, causing differential
genome editing activity in the offspring of each blasto-
mere. To prevent such mosaicism in this context, it may
be required to use GONAD at the zygote (1-cell) stage
(Day 0.4 [~10:00 h] of gestation).
Trans-placental gene delivery to fetuses
Tsukamoto et al., 1995 demonstrated for the first time that
exogenous DNA (encapsulated by liposomes), adminis-
trated through the tail vein of pregnant females, could be
transferred to fetuses via the placenta [51] (shown in
Fig. 2k). Some of the fetuses exhibited blue deposits (β-ga-
lactosidase-catalayzed reaction products when X-Gal was
used as a substrate) throughout the body, showing suc-
cessful gene delivery and expression. Since then, several
laboratories, including ours, have succeeded in delivering
nucleic acids to post-implantation embryos and fetuses
[52, 53]. O’Shea et al. [53] systemically administered short
hairpin (sh) RNAs to mothers during the early post-
implantation stage of gestation, and observed gene knock-
down and defects that phenocopied the null embryo. The
authors concluded that the systemic delivery of shRNAs is
a feasible approach to gene silencing in the embryo. To
date, however, there are no reports of successful germ-line
transmission of the transferred gene using these ap-
proaches. Although a thorough analysis of the distribution
of introduced DNA among fetal tissues has not been per-
formed, delivery to organs in the circulatory system, such
as the heart and blood vessels, may be readily achieved,
since the exogenous DNA is delivered via the placenta
through fetal vessels. It is likely that if guide RNA and
Cas9 are expressed under a tissue-specific promoter, it
could be possible to generate animals with genetic muta-
tions in the target organs or tissues.
Delivery to fetal tissues in utero
Direct delivery to post-implantation embryos and fetuses is
another approach for achieving expression of the gene in
specific target tissues. For example, Tabata and Nakajima,
2001 reported an efficient in utero gene transfer system to
the developing mouse brain using electroporation [54].
The method is performed by surgical exposure of the
uterus carrying the fetuses, direct injection of the exogen-
ous DNA into fetal tissues, and in vivo electroporation at
the injected sites (shown in Fig. 2i). The in utero delivery
approach has been successfully achieved for various tis-
sues, including those involving the skin [55], lungs [56],
and brain [57]. However, examples of targeting to germ
cells at the embryonic stage do not exist because the germ
cell tissue and lineage is very poorly developed at this
stage. Even though such targeted gene delivery approaches
to fetal tissues are useful for studies intended for fetal gen-
ome editing, they cannot be used for achieving germ-line
transmittable mutations.
In vivo delivery to ovarian tissues
There are a few examples of delivering exogenous DNA
to ovarian cells either through viral vectors (Gordon
2001 [58]) or liposomal delivery systems (Shimizu et al.,
2004 [59]). Gordon 2001 [58] reported infecting ovarian
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cells and oocytes by direct injection of adenoviral vectors
into the medulla of an ovary. However, no transduction of
oocytes was observed, despite administering high doses of
viral particles. Shimizu et al., 2004 [59] injected liposo-
mally encapsulated plasmid DNA in to the medullae of
porcine ovaries. The plasmid encoded porcine growth dif-
ferentiation factor-9 (GDF-9), a growth-stimulating factor
belonging to the TGF-β family of proteins is expressed
specifically in immature oocytes. The injection resulted in
an increased growth of immature follicles and led to an in-
crease in the number of secondary and tertiary follicles
[59]. The authors attributed this phenomenon to an in-
creased production of GDF9 in the transfected ovaries;
however, they did not report the detailed localization of
gene products in the ovary expressed from the introduced
DNA.
We explored another strategy, delivering plasmid DNA
to ovarian cells (including oocytes) by intraovarian injec-
tion, followed by in vivo electroporation [60] (shown in
Fig. 2j). In these experiments, we demonstrated that about
20 μl solution can be injected into an ovary at the weaning
age. Histological examination of the ovaries indicated that
8–60 % of the follicles exhibited reporter (lacZ)-derived
blue deposits. Some oocytes that were surrounded by one
or two follicular layers (but not those surrounded by
multi-layered follicles) were also positive for staining for
lacZ activity. We noted exogenous gene expression up to
about 1 week after the procedure [60]. Interestingly, Yang
et al., 2007 used a similar approach to ours and reported
that the DNA injected into the ovary was incorporated
into the oocytes, and that the oocytes that matured were
ovulated after hormonal stimulation [61]. They further ob-
served that the ovulated oocytes resulted in transmission
of exogenous DNA to the F0 offspring derived from them.
This illustrates the possibility of Tg mouse production
with relative ease by ovarian delivery, although it remains
unclear how the introduced exogenous DNA is incorpo-
rated into the oocytes within an ovary, or how it is trans-
mitted to the F0 offspring via fertilization. It will be
interesting to test whether direct delivery of genome-
editing components to ovaries in situ can edit the genome
of immature oocytes, and whether they develop further
into oocytes capable of generating genetically modified
animals.
In vivo delivery to male gonadal tissues
Testis-mediated gene transfer (TMGT)
We demonstrated for the first time that the plasmid
DNA injected into the interstitial space of testis was de-
tected in the cauda epididymis, up to 1 week after DNA
injection [62]. This suggests that testicular spermatozoa
can receive exogenous DNA and can then mature and
be transferred to the cauda epididymis (shown in Fig. 3l).
Others have also reported injecting plasmid DNAs to
testicular spermatozoa using a glass pipette or 30-G nee-
dle [63–65]. Blanchard and Boekelheide, 1997 delivered
an adenovirus vector to the interstitial compartment of
adult rat testes by intratesticular injection and found
transgene expression in Leydig cells [65]. Muramatsu,
2000 demonstrated that the intratesticular injection of
DNA and subsequent in vivo electroporation resulted in
the delivery of DNA to testicular spermatozoa as well as
to interstitial cells [66].
When males injected with exogenous DNA using the
intratesticular injection methods were mated to superovu-
lated females, transmission and expression of the DNA
was verified at the blastocysts and fetuses [67–71]. This
method, based on gene delivery to offspring via testis and
subsequent natural fertilization by mating with females, is
termed “testis-mediated gene transfer” (TMGT) [70], and
serves as a more conventional and simpler approach for
the production of Tg mice, with several laboratories hav-
ing successfully used this technology [72–74]. However,
the technology has been debated for its suitability as a
commonly-usable method for generating transgenic
models because, first, the transgene insertion is not guar-
anteed in every sperm. To ensure the success of each
transgenic project, a vast number of offspring needs to be
screened for the presence of transgene and analyzed for
transgene expression before establishing a breeder colony.
Fig. 3 In vivo delivery to pre-implantation embryos, fetuses and
ovarian tissues
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Second, exogenous DNA introduced by the TMGT is
mainly limited to the interstitial space of each testis. It
should be noted that although there are some reports
showing that exogenous DNA delivered to seminiferous
tubules (ST) can yield Tg offspring [73], it is rare that
DNA will enter into the lumen of the ST containing
spermatogonial (immature sperm) stem cells that later de-
velop into mature sperm cells [75]. Third, in this method,
it is observed that the DNA transmitted to the offspring
occasionally gets fragmented, making it unsuitable for Tg
animal production [76]. Lastly, the copy number of plas-
mid DNA transmitted to the offspring after mating
TMGT-treated males with normal females was below 1
copy per cell [70], and it can therefore be very difficult to
detect the transgene by genomic Southern blotting. Al-
though TMGT has such problems, it still holds some
promise for use as a tool for KO animal production
through sequence-specific nucleases (ZFNs, TALENs or
CRISPR/Cas9) that cause mutations through a hit-and-
run mechanism and do not require chromosomal integra-
tion of transgenes into the sperm genome.
ST-mediated gene delivery
ST-mediated gene delivery is usually performed by the dir-
ect injection of DNA into the lumen of STs exposed above
the testicular capsule [65, 77, 78], or of STs via rete testis,
by a micromanipulator-controlled glass micropipette [79]
(shown in Fig. 3m). Through ST-mediated delivery, the
likelihood of delivering nucleic acids to spermatogonia and
other differentiated spermatogenic cells, such as spermatid
and spermatocytes, is higher compared to that achieved by
TMGT. In fact, successful delivery to spermatogenic cells
was achieved by many groups [65, 77, 78, 80], although
gene transmission after the natural mating of treated males
with females was not sufficiently examined. For example,
while Yamazaki et al., 2000 [78] provided no evidence for
gene transmission to the offspring, Celebi et al., 2000 [80],
showed that the transgene was transmitted to the offspring,
but nevertheless remained episomal, detected in the tail of
young animals but not adults. It was therefore concluded
that the plasmid was lost during the numerous germ cell
divisions. These observations and reports suggest that ST-
mediated gene delivery can also be a tool to create
genome-edited KO animals as an alternative to the widely
used zygote injection-based genome editing.
Gene delivery via vas deferens
Huguet and Esponda, 1998, first demonstrated that injec-
tion of a liposome-DNA complex into the lumen of the
vas deferens, using a glass micropipette, could deliver the
DNA to mature spermatozoa in the lumen of the proximal
region of the vas deferens [81] (shown in Fig. 3n). The
same group also showed that 13.3 % of the epithelial cells
of the vas deferens received the DNA by this method [82].
However, gene transmission to offspring via mating with
females was not demonstrated by this method. This
approach seems to be potentially useful because it can dir-
ectly deliver nucleic acids to mature spermatozoa, which
would be ejaculated during mating soon after. Addition-
ally, gene delivery via the vas deferens is technically
simpler and more convenient than ST-mediated gene de-
livery, since the vas deferens lumens are relatively larger
than those of STs.
Nucleic acids delivery to the cauda epididymis
The cauda epididymis is the site where sperm undergo
final maturation and also is the site of sperm storage. Using
a glass microcapillary needle, Esponda and Carballada,
2009 injected 1–2 μl of the DNA/liposome mixture into
the lumen of the distal region of mouse cauda epididymis
and detected fluorescence in the nucleus and cytoplasm of
epithelial cells [83] (shown in Fig. 3o). Kirby et al., 2004
also reported a similar strategy where they instilled DNA
into the lumen of an initial segment tubule by in vivo elec-
troporation [84]. Because the spermatozoa in the cauda
epididymis are routinely used for IVF experiments, it is
possible that the spermatozoa in vivo electroporated with
genome editing-related components has a high likelihood
of contributing to the generation of offspring with mutated
alleles at the target locus via IVF or natural mating.
Conclusion
Old methods: As described above, there are several tested
and reported methods for gene delivery to germ cells, all
of which have been explored as possible alternatives to PI-
based transgenesis. While none of these have been used as
routine approaches for producing Tg animals, PI-based
Fig. 4 In vivo delivery to male gonadal tissues
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transgenesis is by far the most promising and reliable
method: it has been thoroughly tested, is reproducible,
and is practiced in hundreds of labs worldwide. The PI
method, however, requires expensive micromanipulator
systems, special skills in the technicians that operate the
equipment, ex vivo handling of isolated eggs, and surgical
transfer of manipulated eggs to a recipient animal.
New methods: Compared to the most commonly used
PI method, the recently reported in vitro electroporation-
based methods that deliver nucleic acids to pre-
implantation embryos, and the GONAD method that de-
livers nucleic acids to embryos in situ in the oviducts, have
introduced a new era of generating genome-edited ani-
mals in a simplified manner. The GONAD system in par-
ticular clearly obviates the need for special equipment,
isolation of embryos, complex microinjection steps, or
microsurgery technicians, all of which are necessary for
the PI-based methods.
Old methods revisited: Numerous non-PI methods
which can successfully deliver nucleic acids components,
even though they fail to achieve germ line transmission,
could breathe new life into this area of research because
of newer genome editing tools that do not require inte-
gration into the genome. In our literature search, we
found as many as 15 different routes of delivering nu-
cleic acids to eggs, sperm, gonadal tissues, embryos, and
fetuses (outlined in Figs. 2, 3 and 4). Nearly half or more
of these routes seem to be easily adapted to genome
editing using the newer techniques, particularly the
CRISPR/Cas9 system, since they need be at the genomic
site only for a brief period and do not need to be inte-
grated into the genome. Finally, the CRISPR system can
accomplish precise genome editing without leaving any
foot-prints on the genome. The CRISPR system is rap-
idly evolving by the constant addition of new and im-
proved nucleases to its toolbox [85–88]; by using such
tools and by revisiting the various delivery approaches
discussed in this review, animal genome-editing technol-
ogy can become even more versatile and efficient in the
years to come.
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